• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Celularity Inc. (Amendment)

    2/4/22 12:07:48 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CELU alert in real time by email
    SC 13G/A 1 gxgx13ga31dec2021.htm Converted by EDGARwiz

    CUSIP NO. 151190105

    SCHEDULE 13G/A

    PAGE 1 OF 10 PAGES


                               

    ===============================================================================

                               

                                      UNITED STATES                                 

                           SECURITIES AND EXCHANGE COMMISSION                       

                                 WASHINGTON, D.C. 20549                             

                               

                                      SCHEDULE 13G/A                                 

                               

                        Under the Securities Exchange Act of 1934                   

                                    (Amendment No. 1)*                             

                             

                               

    CELULARITY INC. (FORMERLY KNOWN AS GX ACQUISITION CORP.)

    -------------------------------------------------------------------------------

                                    (Name of Issuer)                                

                               

                               

    Class A common stock, $0.0001 par value per share

    -------------------------------------------------------------------------------

                             (Title of Class of Securities)                         

                               


                                       151190105

    -------------------------------------------------------------------------------

                                     (CUSIP Number)                                 

                               


    December 31, 2021

    -------------------------------------------------------------------------------

                 (Date of Event Which Requires Filing of This Statement)            

                               

    Check the appropriate box to designate the rule pursuant to which this Schedule

    is filed:                  

                                 [ ] Rule 13d-1(b)                                  

                                 [X] Rule 13d-1(c)                                  

                                 [ ] Rule 13d-1(d)                                  

                                           

    * The remainder of this cover page shall be filled out for a reporting person's

    initial filing on this form with respect to the subject class of securities, and

    for any subsequent   amendment   containing   information  which  would  alter

    disclosures provided in a prior cover page.                                     

                               

    The information required on the remainder of this cover page shall not be deemed

    to be "filed" for the purpose of Section 18 of the  Securities  Exchange  Act of

    1934 ("Act") or otherwise subject to the liabilities of that section of the Act

    but shall be  subject  to all other  provisions  of the Act  (however, see the

    Notes).



    CUSIP NO. 151190105

    SCHEDULE 13G/A

    PAGE 2 OF 10 PAGES


    --------------------------------------------------------------------------------

    1.               NAME OF REPORTING PERSON/S.S. OR I.R.S. IDENTIFICATION       

                      NO. OF ABOVE PERSON                                          

                               

                      WEISS ASSET MANAGEMENT LP                                  

    --------------------------------------------------------------------------------

    2.                CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   

                     (A) [ ]  

                     (B) [ ]   

    --------------------------------------------------------------------------------

    3.                SEC USE ONLY                                                 

                               

                               

    --------------------------------------------------------------------------------

    4.                CITIZENSHIP OR PLACE OF ORGANIZATION                         

                               

                      DELAWARE

    --------------------------------------------------------------------------------

                                   5.     SOLE VOTING POWER                        

                               

                                          0                                        

       NUMBER OF                  --------------------------------------------------

        SHARES                     6.     SHARED VOTING POWER                      

     BENEFICIALLY              

    OWNED BY                          0               

     EACH                      --------------------------------------------------

      REPORTING                    7.     SOLE DISPOSITIVE POWER                  

       PERSON                  

        WITH:                             0                                       

                                  --------------------------------------------------

                                   8.     SHARED DISPOSITIVE POWER                

                               

                                          0

    --------------------------------------------------------------------------------

    9.                AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                               

                      0

    --------------------------------------------------------------------------------

    10.               CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES        

                      CERTAIN SHARES*                                          [ ]

    --------------------------------------------------------------------------------

    11.               PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)           

                               

                      0.00%     

    --------------------------------------------------------------------------------

    12.               TYPE OF REPORTING PERSON*                                  

                               

                      IA – Investment Adviser                             




    CUSIP NO. 151190105

    SCHEDULE 13G/A

    PAGE 3 OF 10 PAGES


    --------------------------------------------------------------------------------

    1.               NAME OF REPORTING PERSON/S.S. OR I.R.S. IDENTIFICATION       

                      NO. OF ABOVE PERSON                                          

                               

                      BIP GP LLC                                  

    --------------------------------------------------------------------------------

    2.                CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   

                     (A) [ ]  

                     (B) [ ]   

    --------------------------------------------------------------------------------

    3.                SEC USE ONLY                                                 

                               

                               

    --------------------------------------------------------------------------------

    4.                CITIZENSHIP OR PLACE OF ORGANIZATION                         

                               

                      DELAWARE

    --------------------------------------------------------------------------------

                                   5.     SOLE VOTING POWER                        

                               

                                          0                                        

       NUMBER OF                  --------------------------------------------------

        SHARES                     6.     SHARED VOTING POWER                      

     BENEFICIALLY              

    OWNED BY                          0               

     EACH                      --------------------------------------------------

      REPORTING                    7.     SOLE DISPOSITIVE POWER                  

       PERSON                  

        WITH:                             0                                       

                                  --------------------------------------------------

                                   8.     SHARED DISPOSITIVE POWER                

                               

                                          0

    --------------------------------------------------------------------------------

    9.                AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                               

                      0

    --------------------------------------------------------------------------------

    10.               CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES        

                      CERTAIN SHARES*                                          [ ]

    --------------------------------------------------------------------------------

    11.               PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)           

                               

                      0.00%     

    --------------------------------------------------------------------------------

    12.               TYPE OF REPORTING PERSON*                                  

                               

                      00 – Limited Liability Company                             



    CUSIP NO. 151190105

    SCHEDULE 13G/A

    PAGE 4 OF 10 PAGES


    --------------------------------------------------------------------------------

    1.               NAME OF REPORTING PERSON/S.S. OR I.R.S. IDENTIFICATION       

                      NO. OF ABOVE PERSON                                          

                               

                      WAM GP LLC                                  

    --------------------------------------------------------------------------------

    2.                CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   

                     (A) [ ]  

                     (B) [ ]   

    --------------------------------------------------------------------------------

    3.                SEC USE ONLY                                                 

                               

                               

    --------------------------------------------------------------------------------

    4.                CITIZENSHIP OR PLACE OF ORGANIZATION                         

                               

                      DELAWARE

    --------------------------------------------------------------------------------

                                   5.     SOLE VOTING POWER                        

                               

                                          0                                        

       NUMBER OF                  --------------------------------------------------

        SHARES                     6.     SHARED VOTING POWER                      

     BENEFICIALLY              

    OWNED BY                          0               

     EACH                      --------------------------------------------------

      REPORTING                    7.     SOLE DISPOSITIVE POWER                  

       PERSON                  

        WITH:                             0                                       

                                  --------------------------------------------------

                                   8.     SHARED DISPOSITIVE POWER                

                               

                                          0

    --------------------------------------------------------------------------------

    9.                AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                               

                      0

    --------------------------------------------------------------------------------

    10.               CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES        

                      CERTAIN SHARES*                                          [ ]

    --------------------------------------------------------------------------------

    11.               PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)           

                               

                      0.00%     

    --------------------------------------------------------------------------------

    12.               TYPE OF REPORTING PERSON*                                  

                               

                      HC – Parent Holding Company/Control Person                            





    CUSIP NO. 151190105

    SCHEDULE 13G/A

    PAGE 5 OF 10 PAGES


    --------------------------------------------------------------------------------

    1.               NAME OF REPORTING PERSON/S.S. OR I.R.S. IDENTIFICATION      

                      NO. OF ABOVE PERSON                                         

                               

                      ANDREW M. WEISS, PH.D.                                      

    --------------------------------------------------------------------------------

    2.                CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   

                      (A) [ ]

                      (B) [ ]   

    --------------------------------------------------------------------------------

    3.                SEC USE ONLY                                                

                               

                               

    --------------------------------------------------------------------------------

    4.                CITIZENSHIP OR PLACE OF ORGANIZATION                        

                               

                      USA      

    --------------------------------------------------------------------------------

                                   5.     SOLE VOTING POWER                       

                               

                                          0                                       

       NUMBER OF                  --------------------------------------------------

        SHARES                     6.     SHARED VOTING POWER                      

     BENEFICIALLY              

    OWNED BY                          0               

     EACH                      --------------------------------------------------

      REPORTING                    7.     SOLE DISPOSITIVE POWER                  

       PERSON                  

        WITH:                             0                                       

                                  --------------------------------------------------

                                   8.     SHARED DISPOSITIVE POWER               

                               

                                          0

    --------------------------------------------------------------------------------

    9.                AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                               

                      0

    --------------------------------------------------------------------------------

    10.               CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES       

                      CERTAIN SHARES*                                          [ ]

    --------------------------------------------------------------------------------

    11.               PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)           

                               

                      0.00%    

    --------------------------------------------------------------------------------

    12.               TYPE OF REPORTING PERSON*                                  

                               

                      HC – Parent Holding Company/Control Person       




    CUSIP NO. 151190105

    SCHEDULE 13G/A

    PAGE 6 OF 10 PAGES


    ITEM 1.                    

                               

          (a) Name of Issuer:  CELULARITY INC. (FORMERLY KNOWN AS GX ACQUISITION CORP.)  

                             ------------------------------------------------

                              

          (b) Address of Issuer's Principal Executive Offices:    

    170 Park Ave

    Florham Park, NJ 07932

                    ------------------------------------------------                   ITEM 2.                    

                               

          (a) and (c): Name and Citizenship of Persons Filing:                    

                               

     (i)   BIP GP LLC, a Delaware limited liability company (“BIP GP”).

     (ii)  Weiss Asset Management LP, a Delaware limited partnership ("Weiss        Asset Management").

    (iii)   WAM GP LLC, a Delaware limited liability company (“WAM GP”).

           (iv)  Andrew M. Weiss, Ph.D., a United States citizen (“Andrew Weiss”).      

                               

          (b):  Address of Principal Business Office:                            

                               

          BIP GP, Weiss Asset Management, WAM GP, and Andrew Weiss have a business    

          address of 222 Berkeley St., 16th floor, Boston, Massachusetts 02116

                               

          (d) Title of Class of Securities: Class A common stock, $0.0001 par value per share

             

    -------------------------------------                        

          (e) CUSIP Number: 151190105

                           ------------------                      

                 

    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B), CHECK

            WHETHER THE PERSON FILING IS A:                                         

                               

         (a)  [ ] Broker or Dealer registered under Section 15 of the Act           

                  (15 U.S.C. 78o).                                                  

         (b)  [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).    

         (c)  [ ] Insurance Company as defined in section 3(a)(19) of the Act       

                  (15 U.S.C. 78c).                                                  

         (d)  [ ] Investment  Company  registered  under section 8 of the Investment

                  Company Act of 1940 (15 U.S.C. 80a-8).                            

         (e)  [ ] Investment  Adviser registered under section 203 of the Investment

                  Advisers Act or under the laws of any State                       

         (f)  [ ] Employee  Benefit  Plan,  Pension  fund  which is  subject to the

                  provisions of the Employee  Retirement  Income Security Act of    

                  1974 or Endowment Fund; see Section 240.13d-1(b)(1)(ii)(F)        

         (g)  [ ] A Parent Holding Company  or  control  person, in  accordance with

                  Section 240.13d-1(b)(ii)(G)                     

         (h)  [ ] A Savings  Association  as defined in Section  3(b) of the Federal

                  Deposit Insurance Act (12 U.S.C. 1813)                            

         (i)  [ ] A  Church  Plan  that  is  excluded  from  the  definition  of  an

                  investment  company under Section  3(c)(14) of the Investment     

                  Company Act of 1940 (15 U.S.C. 80a-3)                             

         (j)  [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(J)          

                               



    CUSIP NO. 151190105

    SCHEDULE 13G/A

    PAGE 7 OF 10 PAGES


    ITEM 4.   OWNERSHIP        

                               

    BIP GP*                                             

          (a) Amount Beneficially Owned:  0

                                         -------------------------------------------

          (b) Percent of Class:  0.00%                                               

                                ----------------------------------------------------

          (c) Number of shares as to which such person has:                         

                               

            (i)   sole power to vote or to direct the vote:   0                    

                                                             -----------------------

            (ii)  shared power to vote or to direct the vote:  0

                                                               ---------------------

            (iii) sole power to dispose or to direct the disposition of:  0         

                                                                          ----------

            (iv)  shared power to dispose or to direct the disposition of: 0

                                                                           ----------                  


    WEISS ASSET MANAGEMENT*                                             

          (a) Amount Beneficially Owned:  0

                                         -------------------------------------------

          (b) Percent of Class:  0.00%                                               

                                ----------------------------------------------------

          (c) Number of shares as to which such person has:                         

                               

            (i)   sole power to vote or to direct the vote:   0                    

                                                             -----------------------

            (ii)  shared power to vote or to direct the vote:  0

                                                               ---------------------

            (iii) sole power to dispose or to direct the disposition of:  0         

                                                                          ----------

            (iv)  shared power to dispose or to direct the disposition of: 0

                                                                           ----------                  


    WAM GP*                                             

          (a) Amount Beneficially Owned:  0

                                         -------------------------------------------

          (b) Percent of Class:  0.00%                                            

                                ----------------------------------------------------

          (c) Number of shares as to which such person has:                         

                               

            (i)   sole power to vote or to direct the vote:    0                    

                                                             -----------------------

            (ii)  shared power to vote or to direct the vote:  0

                                                               ---------------------

            (iii) sole power to dispose or to direct the disposition of:  0         

                                                                          ----------

            (iv)  shared power to dispose or to direct the disposition of: 0

                                                                           ----------                     


      ANDREW M. WEISS, PH.D.*                         

          (a) Amount Beneficially Owned:  0

                                         -------------------------------------------

          (b) Percent of Class:  0.00%                                           

                                ----------------------------------------------------

          (c) Number of shares as to which such person has:                         



    CUSIP NO. 151190105

    SCHEDULE 13G/A

    PAGE 8 OF 10 PAGES


                               

            (i)  sole power to vote or to direct the vote:    0                    

                                                            ------------------------

            (ii) shared power to vote or to direct the vote:  0

        

        -----------------------

            (iii) sole power to dispose or to direct the disposition of:   0         

                    

       -----------

            (iv) shared power to dispose or to direct the disposition of: 0

                                                                          -----------


    -----------------------    

    * Shares reported for BIP GP include shares beneficially owned by a private investment partnership (the “Partnership”) of which BIP GP is the sole general partner. Weiss Asset Management is the sole investment manager to the Partnership. WAM GP is the sole general partner of Weiss Asset Management. Andrew Weiss is the managing member of WAM GP and BIP GP. Shares reported for WAM GP, Andrew Weiss and Weiss Asset Management include shares beneficially owned by the Partnership (and reported above for BIP GP).


    Each of BIP GP, WAM GP, Weiss Asset Management, and Andrew Weiss disclaims beneficial ownership of the shares reported herein as beneficially owned by each except to the extent of their respective pecuniary interest therein. The percent of class computations are based on 123,464,113 shares of Class A common stock issued and outstanding as of November 9, 2021 as reported in the Form 10-Q of the Issuer, which was filed with the SEC on November 12, 2021.



    ITEM 5.   OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS                         

                               

             If this statement is being filed to report the fact that as of the date

    hereof the reporting person has ceased to be the beneficial  owner of more than

    five percent of the class of securities, check the following [X].

                               

                               

    ITEM 6.   OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON       

                               

          Not Applicable       

                               

                               

    ITEM 7.  IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE

             SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL

             PERSON            

                               

          See Item 4.       

                               

                               

    ITEM 8.   IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP             

                               

          Not Applicable       



    ITEM 9.   NOTICE OF DISSOLUTION OF GROUP                                        

                               

          Not Applicable                                  



    CUSIP NO. 151190105

    SCHEDULE 13G/A

    PAGE 9 OF 10 PAGES


    ITEM 10.  CERTIFICATION    

                               

    By signing below I certify that, to the best of my knowledge and belief, the

    securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.    



    ITEM 11.  MATERIALS TO BE FILED AS EXHIBITS


    Exhibit 1

    Joint Filing Agreement    


      SIGNATURE                                   

                               

    After reasonable inquiry and to the best of my knowledge and belief, I hereby

    certify that the information set forth in this statement is true, complete and

    correct.                   

                               

    Dated:  February 4, 2022     

                               WEISS ASSET MANAGEMENT LP            


    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Chief Compliance Officer



    BIP GP LLC            


    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Chief Compliance Officer



    WAM GP LLC

        

    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Chief Compliance Officer



    ANDREW M. WEISS, PH.D.                         

        

    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Attorney-in-Fact for Andrew Weiss**


    _____

    ** Duly authorized under Power of Attorney incorporated herein by reference to the exhibit to the Form 13G/A filed by Weiss Asset Management LP on January 25, 2017 in respect of its holding in Quinpario Acquisition Corp. 2.



    CUSIP NO. 151190105

    SCHEDULE 13G/A

    PAGE 10 OF 10 PAGES


    Exhibit 1

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, Weiss Asset Management LP, BIP GP LLC, WAM GP LLC, and Andrew M. Weiss, hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13G and/or 13D (including any and all amendments thereto) with respect to the Class A common stock, $0.0001 par value per share of GX ACQUISITION CORP.), and further agree that this Joint Filing Agreement, as may be amended from time to time, shall be included as an Exhibit to such joint filings.

     

    The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and/or 13D and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

     

    This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument.

     

    IN WITNESS WHEREOF, the undersigned have executed this Agreement as of March 31, 2021.


                               WEISS ASSET MANAGEMENT LP            


    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Chief Compliance Officer



    BIP GP LLC            


    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Chief Compliance Officer


                                                                                                             

    WAM GP LLC

        

    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Chief Compliance Officer



    ANDREW M. WEISS, PH.D.                         

        

    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Attorney-in-Fact for Andrew Weiss**


    ** Duly authorized under Power of Attorney incorporated herein by reference to the exhibit to the Form 13G/A filed by Weiss Asset Management LP on January 25, 2017 in respect of its holding in Quinpario Acquisition Corp. 2.



    Get the next $CELU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CELU

    DatePrice TargetRatingAnalyst
    1/30/2023$5.00 → $1.00Equal-Weight → Underweight
    Morgan Stanley
    12/22/2022Outperform → Perform
    Oppenheimer
    6/22/2022$15.00Buy
    H.C. Wainwright
    4/6/2022$10.00Buy → Hold
    Truist
    1/28/2022$9.00Outperform
    Oppenheimer
    11/24/2021$9.00Equal-Weight
    Morgan Stanley
    10/19/2021$12.00Buy
    Truist Securities
    More analyst ratings

    $CELU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Barach Philip Alan

    3 - Celularity Inc (0001752828) (Issuer)

    4/24/26 6:41:27 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Barach Daniele Wolf

    3 - Celularity Inc (0001752828) (Issuer)

    4/24/26 6:41:04 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Philip & Daniele Barach Family Trust

    3 - Celularity Inc (0001752828) (Issuer)

    4/24/26 6:40:13 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

    FLORHAM PARK, N.J. and ORLANDO, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, and Fountain Life Management, LLC ("Fountain Life"), a leading healthy longevity company delivering a next-generation preventive health model through advanced diagnostics, restorative therapeutics, and AI-driven health intelligence, today announced the availability of cenplacel-L, a placental-derived allogeneic investigational cell therapy, for investigational use by licensed physicians in the State of Florida under recently enacted legislation supporting responsi

    6/4/26 8:00:00 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity Releases CEO Letter to Shareholders

    FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today announced that it has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Celularity's Founder, Chairman, and Chief Executive Officer, to the Investor Relations section of its website. The letter is also included below. Dear Fellow Shareholders, I want to take this opportunity to provide an important update on the developments at Celularity over the past several months particularly in the context of evolving clinical and regulatory progress.

    6/3/26 4:15:00 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity Appoints Rick Gonzalez as Chief Commercial Officer

    FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular and regenerative therapies, today announced the appointment of Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026. In this role, Mr. Gonzalez will oversee global commercial strategy and execution for cenplacel-L, Lifebank and the Company's broader regenerative medicine portfolio, and will report to Robert J. Hariri, M.D., Ph.D., Celularity's Chairman, Chief Executive Officer and Founder. "Rick's appointment comes at an important time for Celularity as we conti

    6/3/26 8:00:00 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lim Kok Thay bought $5,331,335 worth of shares (21,410,983 units at $0.25) (SEC Form 4)

    4 - Celularity Inc (0001752828) (Issuer)

    1/17/24 5:22:20 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hariri Robert J bought $2,984,294 worth of shares (18,422,124 units at $0.16), increasing direct ownership by 182% to 28,570,434 units (SEC Form 4)

    4 - Celularity Inc (0001752828) (Issuer)

    10/10/23 9:48:11 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Celularity downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Celularity from Equal-Weight to Underweight and set a new price target of $1.00 from $5.00 previously

    1/30/23 7:11:17 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity downgraded by Oppenheimer

    Oppenheimer downgraded Celularity from Outperform to Perform

    12/22/22 7:40:17 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Celularity with a new price target

    H.C. Wainwright initiated coverage of Celularity with a rating of Buy and set a new price target of $15.00

    6/22/22 7:19:25 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    SEC Filings

    View All

    Celularity Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Celularity Inc (0001752828) (Filer)

    6/3/26 5:22:06 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Celularity Inc (0001752828) (Filer)

    5/28/26 4:54:19 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-Q filed by Celularity Inc.

    NT 10-Q - Celularity Inc (0001752828) (Filer)

    5/15/26 4:30:21 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Leadership Updates

    Live Leadership Updates

    View All

    Celularity Appoints Rick Gonzalez as Chief Commercial Officer

    FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular and regenerative therapies, today announced the appointment of Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026. In this role, Mr. Gonzalez will oversee global commercial strategy and execution for cenplacel-L, Lifebank and the Company's broader regenerative medicine portfolio, and will report to Robert J. Hariri, M.D., Ph.D., Celularity's Chairman, Chief Executive Officer and Founder. "Rick's appointment comes at an important time for Celularity as we conti

    6/3/26 8:00:00 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NEXGEL Appoints Ian Blackman as Chief Financial Officer

    Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Ian Blackman, CPA, as Chief Financial Officer. Mr. Blackman will help to advance the closing of the definitive agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity Inc., ("Celularity")

    4/27/26 9:00:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

    3/10/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $CELU
    Financials

    Live finance-specific insights

    View All

    Celularity Provides Corporate Update

    FLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO. Dear Shareholders, I am pleased to share recent developments at Celularity, including an update on our commercial-stage advanced biomaterial products business. Let me start by reiterating what we said in our announcement last week, which is that we are resolutely committed to regaining full compliance with Nasdaq's listing requirements. We acknowledge the importance of timely filings and have been diligently working with our new auditi

    10/22/24 8:30:00 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Celularity Inc. (Amendment)

    SC 13D/A - Celularity Inc (0001752828) (Subject)

    3/15/24 5:32:04 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Celularity Inc. (Amendment)

    SC 13G/A - Celularity Inc (0001752828) (Subject)

    2/8/24 6:00:11 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Celularity Inc. (Amendment)

    SC 13D/A - Celularity Inc (0001752828) (Subject)

    1/17/24 5:15:41 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care